Answers are grounded in this paper and cite their sources.
In recent years, the therapeutic potential of dexmedetomidine in septic shock and sepsis-induced acute kidney injury (SAKI) has garnered increasing attention. While independent studies have demonstrated that dexmedetomidine activates AMP-activated protein kinase (AMPK) and sirtuin 3 (SIRT3) separately, the exact molecular mechanisms remain elusive. Specifically, it is unclear whether the drug operates via direct target engagement or within an interconnected regulatory network. This study employed a multilevel approach combining a retrospective clinical cohort, a clinical validation cohort, computational molecular docking, in vitro surface plasmon resonance analysis, cellular models, and animal experiments to systematically evaluate the efficacy and mechanism of dexmedetomidine in SAKI. Analysis of 704 patients with septic shock from the MIMIC-Ⅳ database revealed that dexmedetomidine treatment was associated with improved renal function recovery and reduced in-hospital mortality. Mechanistically, dexmedetomidine alleviated mitochondrial dysfunction by promoting mitophagy. Crucially, surface plasmon resonance assays confirmed the direct binding of dexmedetomidine to both AMPK and SIRT3, supporting the molecular docking predictions. Knockdown of either AMPK or SIRT3 not only reduced the expression and activity of the other protein but also abrogated dexmedetomidine-induced NAD + elevation and LKB1 deacetylation. These findings confirmed their functional interdependence in the dexmedetomidine-activated positive feedback mechanism. Moreover, dexmedetomidine-enhanced mitophagy and mitochondrial protection were demonstrated to be dependent on this regulatory loop. Inhibition of the AMPK-SIRT3 feedback loop abrogated the beneficial effects of dexmedetomidine on survival and renal injury in a mouse model of SAKI. Consistently, clinical validation further associated dexmedetomidine treatment with improved NAD + status, reduced urinary markers reflecting renal tubular mitochondrial injury and metabolic stress, and better renal recovery in patients with SAKI. These findings indicate that dexmedetomidine ameliorates mitochondrial dysfunction in SAKI by directly engaging and activating an AMPK-SIRT3 positive feedback loop that enhances mitophagy, suggesting its potential as a targeted therapeutic agent for SAKI.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: